
UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …

Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

